nVerses Capital LLC Acquires Shares of 1,600 IQVIA Holdings Inc. (NYSE:IQV)

nVerses Capital LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 1,600 shares of the medical research company’s stock, valued at approximately $379,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. Versant Capital Management Inc lifted its holdings in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after acquiring an additional 110 shares during the last quarter. Opal Wealth Advisors LLC acquired a new stake in IQVIA in the second quarter valued at approximately $27,000. Park Place Capital Corp bought a new stake in shares of IQVIA during the third quarter worth $28,000. Itau Unibanco Holding S.A. bought a new position in shares of IQVIA in the 2nd quarter valued at $29,000. Finally, Rise Advisors LLC bought a new stake in IQVIA during the 1st quarter worth $31,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of recent research reports. Barclays cut their price target on IQVIA from $275.00 to $260.00 and set an “overweight” rating on the stock in a research note on Tuesday. Truist Financial reduced their target price on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a report on Monday. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Monday. Robert W. Baird increased their price objective on IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a report on Friday, September 20th. Finally, Argus raised IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $267.87.

IQVIA Stock Up 0.4 %

IQVIA stock opened at $233.89 on Friday. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The company has a market capitalization of $42.61 billion, a PE ratio of 31.95, a PEG ratio of 2.18 and a beta of 1.49. The firm’s fifty day moving average is $239.09 and its 200 day moving average is $231.35. IQVIA Holdings Inc. has a 12-month low of $167.42 and a 12-month high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same quarter in the prior year, the firm earned $2.22 EPS. The business’s revenue was up 2.3% on a year-over-year basis. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.